Skip to content
10-Q

Quarterly Report

ATYR PHARMA, INC. ATYR

0001339970-26-000033

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 98.05M sh
Shares Diluted Q1 2026 · Mar 31, 2026 98.04M sh
Shares Diluted Q1 2026 · Mar 31, 2025 86.49M sh
Capex Q1 2026 · Mar 31, 2026 $138K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$12.52M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$15.42M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $10.01M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $10.74M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $10.36M
Stockholders Equity Q1 2026 · Mar 31, 2026 $57.93M
Stockholders Equity Q1 2026 · Dec 31, 2025 $67.48M
Current Liabilities Q1 2026 · Mar 31, 2026 $11.7M
Current Liabilities Q1 2026 · Dec 31, 2025 $15.15M
Current Assets Q1 2026 · Mar 31, 2026 $67.58M
Current Assets Q1 2026 · Dec 31, 2025 $80.24M
Total Assets Q1 2026 · Mar 31, 2026 $79.65M
Total Assets Q1 2026 · Dec 31, 2025 $93M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.11
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.17
Eps Basic Q1 2026 · Mar 31, 2026 −$0.11
Eps Basic Q1 2026 · Mar 31, 2025 −$0.17
Sga Expense Q1 2026 · Mar 31, 2026 $4.12M
Sga Expense Q1 2026 · Mar 31, 2025 $3.96M
Rd Expense Q1 2026 · Mar 31, 2026 $7.32M
Rd Expense Q1 2026 · Mar 31, 2025 $11.81M
Net Income Q1 2026 · Mar 31, 2026 −$10.79M
Net Income Q1 2026 · Mar 31, 2025 −$14.88M
Operating Income Q1 2026 · Mar 31, 2026 −$11.44M
Operating Income Q1 2026 · Mar 31, 2025 −$15.77M